Decoding Neurological Disease. Building Medicines.

CELLTIUM is developing precision therapies for CMT1A and related neurological disorders. By combining deep disease biology with the proprietary PRECISION™ platform, we are advancing a more translationally informed approach to drug discovery.

A New Model for Neurotherapeutics
We are integrating disease biology, quantitative phenotyping, and AI into a single translational framework — from target identification to lead optimization.

Targeting the Root Cause of CMT1A
We are advancing a mechanistically distinct small-molecule pipeline for CMT1A, the most common inherited peripheral neuropathy, with a focus on core disease mechanisms and peripheral nerve function.

Where Biology Meets AI
The PRECISION™ platform combines disease-relevant models, high-content phenotypic screening, and multimodal biological data to generate actionable phenomic signatures that guide discovery and lead optimization.

BIO
KOREA
2026

APRIL 28-30

Seoul COEX

Schedule via BIO KOREA Business Partnering or Contact Us.

Partner With Us
We welcome strategic collaborations with pharmaceutical companies, research institutions, and investors who share our commitment to advancing CMT1A therapeutics and the PRECISION™ platform.

Join the Team
Help build the future of precision medicine at the intersection of neuroscience, biology, and AI.

A New Model for Neurotherapeutics We are integrating disease biology, quantitative phenotyping, and AI into a single translational framework — from target identification to lead optimization.

Targeting the Root Cause of CMT1A We are advancing a mechanistically distinct small-molecule pipeline for CMT1A, the most common inherited peripheral neuropathy, with a focus on core disease mechanisms and peripheral nerve function.

Where Biology Meets AI The PRECISION™ platform combines disease-relevant models, high-content phenotypic screening, and multimodal biological data to generate actionable phenomic signatures that guide discovery and lead optimization.

A New Model for Neurotherapeutics
We are integrating disease biology, quantitative phenotyping, and AI into a single translational framework — from target identification to lead optimization.

Targeting the Root Cause of CMT1A
We are advancing a mechanistically distinct small-molecule pipeline for CMT1A, the most common inherited peripheral neuropathy, with a focus on core disease mechanisms and peripheral nerve function.

Where Biology Meets AI
The PRECISION™ platform combines disease-relevant models, high-content phenotypic screening, and multimodal biological data to generate actionable phenomic signatures that guide discovery and lead optimization.